Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
about
Nanomedicine in pulmonary deliveryMonocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease.Nanoparticle approaches against bacterial infectionsTuberculosis chemotherapy: current drug delivery approaches.An update on the use of rifapentine for tuberculosis therapy.Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity.Novel drug delivery systems: desired feat for tuberculosis.Antitubercular inhaled therapy: opportunities, progress and challenges.New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.Fighting tuberculosis: old drugs, new formulations.Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes.Liposomes as drug delivery systems for the treatment of TB.Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.Lipid-based carriers: manufacturing and applications for pulmonary route.'Smart' non-viral delivery systems for targeted delivery of RNAi to the lungs.Liposomal formulations for inhalation.A review of emerging trends in the treatment of tuberculosis.Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.In Vitro Investigation of Influences of Chitosan Nanoparticles on Fluorescein Permeation into Alveolar Macrophages.Lipid-based nanovesicles for nanomedicine.Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.Lipid-based nanocarriers for the oral administration of biopharmaceutics.Soft particle analysis of electrokinetics of biological cells and their model systems.Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery.Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages.Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation.Synthetic nanovaccines for immunotherapy.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization.Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections.Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.Composition influence on pulmonary delivery of rifampicin liposomesTargeted liposomal drug delivery to monocytes and macrophagesInhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis.Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.Liposome-based drug delivery to alveolar macrophages.Preparation of sustained release rifampicin microparticles for inhalation.Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment.Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation.
P2860
Q33572981-17920EF6-43F0-4CA3-A219-9897B8D5BF1EQ33949943-19112F6F-BADA-46CE-B43B-E8F570DD63EBQ34339159-0372A501-A148-442F-9918-6C665A93F8DAQ35069271-C229482E-F3DB-46B9-AC37-2F388D7B3B09Q35084363-01943F33-1AAC-4BF4-B066-42DEF3CE2343Q35549569-BC5626F2-44F2-40A1-AE02-439C6907F487Q35664688-076B6E1F-5C31-4E56-A1A0-8303786E10D0Q36068001-567AE4D5-F87A-40BF-9240-85D5C3C998A5Q37532557-48AC5BFD-EBE9-4A21-8BB8-DB541B30C56FQ37579212-5938EE1E-2103-41B4-9247-26106ACD3ED4Q37861190-929A75CC-E366-4388-980F-A9F676A21FA9Q37949386-9869CFB9-6952-4B2C-BCF6-02AC8CAC381AQ37978509-4234F996-CCB4-44E8-B476-B385E9FA00DBQ38020888-E39BACB0-B721-4765-84C6-13DCAF587DE6Q38074463-51D2316C-C450-49C4-AA48-EED2388594ECQ38126942-A7C85A78-1DC4-43F7-B58A-1F0D2061EAE9Q38264545-DB6C41FC-9CC8-4A68-9EB7-C22B1E89C02EQ38442447-70E678B7-A143-4C36-8CD3-944241F305D4Q38788185-4D0883F1-21CF-4314-AF72-99D8BB44546BQ38813182-8FFFD3E6-EF7C-486D-98D1-A1BDFC7CE9EEQ38939434-D1A169D2-872B-48CA-9163-595F9E460303Q38990887-BB4ECBB3-5A18-40DE-BC5D-96547F5311F4Q39017353-14CFF840-B4BA-4570-BC3C-1EBD9415686CQ39672174-B2F78463-88C9-4FD1-A9D7-5721F0198CD4Q39782529-7DA30BFC-A3FB-4239-B534-74552EDBF097Q39839885-BD1DB18F-AAC8-41CD-94CE-022567067649Q40280801-1D20397E-6BAD-43B6-A9E4-859101315E3EQ40974806-77342A0F-671F-4684-9D6F-ACF195F41240Q41881667-5D372C04-2FFD-42B9-ACB6-3D4A039F67DCQ41931571-B2BA137E-924C-41FA-9BDF-C1136AD1EA23Q41989537-E3279B62-670B-42DA-9105-A117A2784330Q42087785-34A36F99-C786-41BB-B718-D75E89EA89CEQ42108171-6B14B420-274D-4CF9-BBBB-17D082E05862Q42227059-69E5E9B4-73D2-4225-AB71-8BE57F0952CCQ42241235-0604305A-B524-4452-92AB-01428C893BD1Q42712047-9D0B179B-E0D1-4D38-AC90-ADE41B51C441Q44861248-6C4E4E13-A8D5-4A0C-98B4-CE9E500E921BQ44977937-49E84B62-FE63-4C34-B9C0-FE7DB558A463Q45216031-73F37636-3AD1-4BE9-861B-C1650EB79A49Q46099473-9266D77B-008A-4B2D-AC4B-C850404A1A39
P2860
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@en
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@nl
type
label
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@en
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@nl
prefLabel
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@en
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@nl
P2093
P1476
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
@en
P2093
M E Kannan
Paramjit Singh
P356
10.1016/J.IJPHARM.2003.08.017
P407
P50
P577
2004-01-01T00:00:00Z